Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, will be hosting a third-quarter virtual Investor Day. The company has scheduled this event for July 29, 2021; it will begin at 9 a.m. PDT. Included on the event agenda will be a presentation by Tryp’s management team. The presentation will provide updates regarding the company’s psilocybin-for-neuropsychiatric disorders, or PFN(TM) (“PFN”), program. The team will also discuss 2021 milestones. In addition, the agenda features a Q&A session. Tryp executives participating in the event include Greg McKee, chair and CEO; Luke Hayes, CFO; and Jim Gilligan, PhD, president and chief science officer. Interested individuals who are unable to attend can view a replay of the Investor Day on the company’s website for 30 days following the event. “I am excited to showcase the transformative work that Tryp Therapeutics is doing in collaboration with our academic research partners such as the University of Michigan and the University of Florida,” said Tryp chair and CEO Greg McKee in the press release. “The next six months represent an important stage in development for us as we initiate multiple phase 2a clinical trials and move closer to providing additional treatment options for the millions of patients suffering from a variety of chronic pain diseases and eating disorders.”
To register for the event visit, https://ibn.fm/GSUs8
To view the full press release, visit https://ibn.fm/w9tQ5
About Tryp Therapeutics Inc.
Tryp Therapeutics is a pharmaceutical company focused on developing compounds for the treatment of diseases with unmet medical needs through accelerated regulatory pathways. Tryp’s psilocybin-for-neuropsychiatric disorders, or PFN(TM) (“PFN”), program is focused on the development of synthetic psilocybin as a new class of drug for the treatment of chronic pain and eating disorder indications. The company has announced upcoming Phase 2a clinical trials to evaluate its drug products for fibromyalgia and eating disorders. Tryp is also developing a proprietary psilocybin-based product, TRP-8803, that uses a novel formulation and method of delivery to improve the patient experience. For more information about the company, please visit www.TrypTherapeutics.com.
NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.qualitystocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php
